MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
36130300
PubMed Central
PMC10651778
DOI
10.1182/blood.2022016782
PII: S0006-4971(22)01308-8
Knihovny.cz E-zdroje
- MeSH
- lidé MeSH
- mnohočetný myelom * terapie MeSH
- reziduální nádor farmakoterapie MeSH
- sloučeniny boru MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- ixazomib MeSH Prohlížeč
- sloučeniny boru MeSH
- tourmaline MeSH Prohlížeč
Measurable residual disease (MRD) evaluation may help to guide treatment duration in multiple myeloma (MM). Paradoxically, limited longitudinal data exist on MRD during maintenance. We investigated the prognostic value of MRD dynamics in 1280 transplant-eligible and -ineligible patients from the TOURMALINE-MM3 and -MM4 randomized placebo-controlled phase 3 studies of 2-year ixazomib maintenance. MRD status at randomization showed independent prognostic value (median progression-free survival [PFS], 38.6 vs 15.6 months in MRD- vs MRD+ patients; HR, 0.47). However, MRD dynamics during maintenance provided more detailed risk stratification. A 14-month landmark analysis showed prolonged PFS in patients converting from MRD+ to MRD- status vs those with persistent MRD+ status (76.8% vs 27.6% 2-year PFS rates). Prolonged PFS was observed in patients with sustained MRD- status vs those converting from MRD- to MRD+ status (75.0% vs 34.2% 2-year PFS rates). Similar results were observed at a 28-month landmark analysis. Ixazomib maintenance vs placebo improved PFS in patients who were MRD+ at randomization (median, 18.8 vs 11.6 months; HR, 0.65) or at the 14-month landmark (median, 16.8 vs 10.6 months; HR, 0.65); no difference was observed in patients who were MRD-. This is the largest MM population undergoing yearly MRD evaluation during maintenance reported to date. We demonstrate the limited prognostic value of a single-time point MRD evaluation, because MRD dynamics over time substantially impact PFS risk. These findings support MRD- status as a relevant end point during maintenance and confirm the increased progression risk in patients converting to MRD+ from MRD- status. These trials were registered at www.clinicaltrials.gov as #NCT02181413 and #NCT02312258.
Clínica Bupa Reñaca Universidad de Valparaíso Viña del Mar Valparaíso Chile
Clinica Universidad de Navarra Centro de Investigación Médica Aplicada Pamplona Spain
Department of Hematology Charles University Prague Czech Republic
Department of Hematology Shanghai Changzheng Hospital Shanghai China
Medizinische Klinik und Poliklinik 1 Universitätsklinikum TU Dresden Dresden Germany
Zobrazit více v PubMed
Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches. Front Oncol. 2020;10:860. PubMed PMC
Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–5999. PubMed PMC
Cavo M, San-Miguel JFF, Usmani SZ, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. Blood. 2022;139(6):835–844. PubMed PMC
San-Miguel JF, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity with daratumumab in newly diagnosed multiple myeloma: MAIA and ALCYONE. Blood. 2022;139(4):492–501. PubMed PMC
Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10):1139–1149. PubMed PMC
Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–2464. PubMed PMC
Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784–792. PubMed
Oliva S, Bruinink DHO, Rihova L, et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. Blood Cancer J. 2021;11(6):106. PubMed PMC
Diamond B, Korde N, Lesokhin AM, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8(6):e422–e432. PubMed
de Tute RM, Pawlyn C, Cairns DA, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40(25):2889–2900. PubMed
Bal S, Costa LJ. Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy. Lancet Haematol. 2021;8(6):e386–e387. PubMed
Anderson KC, Auclair D, Kelloff GJ, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017;23(15):3980–3993. PubMed
Martinez-Lopez J, Wong SW, Shah N, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4(14):3295–3301. PubMed PMC
Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393(10168):253–264. PubMed
Dimopoulos MA, Spicka I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020;38(34):4030–4041. PubMed PMC
Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25):2900–2910. PubMed PMC
Mohan M, Kendrick S, Szabo A, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6(3):808–817. PubMed PMC
Lahuerta JJ, Paiva B, Jimenez de Ubieto A, et al. Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. Blood Adv. 2021;5(5):1340–1343. PubMed PMC
Gu J, Liu J, Chen M, Huang B, Li J. Longitudinal flow cytometry identified “minimal residual disease“ (MRD) evolution patterns for predicting the prognosis of patients with transplant-eligible multiple myeloma. Biol Blood Marrow Transplant. 2018;24(12):2568–2574. PubMed
Paiva B, Cedena MT, Puig N, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016;127(25):3165–3174. PubMed
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. PubMed
Gozzetti A, Raspadori D, Pacelli P, et al. Minimal residual disease (MRD) at 10-6 measured by next generation flow (NGF) during daratumumab consolidation therapy: analysis at 18 months follow-up of DART4MM study (Daratumumab Treatment for Multiple Myeloma Eradication) Blood. 2020;136(Supplement 1):7–8.
Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–3079. PubMed PMC
Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103. PubMed PMC
Garderet L, Kharroubi-Lakouas D, roos Weil D, et al. The role of PET-MRI in multiple myeloma patients. Blood. 2020;136(Supplement 1):12. 12.
Gonzalez-Velez M, Arribas M, Kosiorek HE, et al. Improving the definition of response assessment: prognostic value of minimal residual disease combined with PET/CT at day 100 post autologous stem cell transplantation in multiple myeloma. Blood. 2020;136(Supplement 1):33–34.
Zajec M, Langerhorst P, VanDuijn MM, et al. Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins. Clin Chem. 2020;66(3):421–433. PubMed
Langerhorst P, Noori S, Zajec M, et al. Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow. Clin Chem. 2021;67(12):1689–1698. PubMed
Sanoja-Flores L, Flores-Montero J, Puig N, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019;134(24):2218–2222. PubMed PMC
Mazzotti C, Buisson L, Maheo S, et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2018;2(21):2811–2813. PubMed PMC
Holstein SA, Howard A, Avigan D, et al. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2020;26(10):e247–e255. PubMed PMC
Krishnan A, Hoering A, Hari P, Sexton R, Orlowski RZ. Phase III study of daratumumab/rhuph20 (nsc-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapyin patients with multiple myeloma (MM) using minimal residual disease todirect therapy duration (DRAMMATIC study): SWOG s1803. Blood. 2020;136(Supplement 1):21–22.
ClinicalTrials.gov
NCT02312258, NCT02181413